Xilio Therapeutics

Xilio Therapeutics

  • Founded: 2018
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Solid Tumors
  • Drug types: ONC
  • Lead product: XTX101
  • Product link: https://xiliotx.com/pipeline
  • Funding: $118M IPO Oct 2021; $95M C Feb 2021; $100.5M B Mar 2020; $30M A Sep 2018
  • Investors: F-Prime Capital Partners, Atlas Venture, Takeda



job board

Short description:

Cancer Immunotherapies

Drug notes:

XTX202 Clin1 solid tumors; XTX301 Clin1 solid tumors

Long description:

Xilio Therapeutics is developing immunotherapies to improve cancer patient outcomes. Immunotherapy is the latest successful frontier in cancer treatment. Xilio is using their proprietary geographically precise solutions (GPS) platform to engineer novel molecules, including cytokines, to optimize therapeutics. The GPS platform designs molecules that only get activated in the tumor microenvironment, thus enhancing the molecules’ anti-tumor activity and localizing this potent activity. This has the benefit of reducing side effects seen in systemic therapies. Xilio is developing a range of molecules, with promising preclinical data for their lead candidates that show the potential of the system to create tumor-selective therapeutics. Xilio is also hoping to apply the GPS platform to inflammatory diseases.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com